Peptide Interaction Checker

BPC-157 and TB-500 are commonly co-administered in research settings for synergistic tissue repair — BPC-157 is more localized while TB-500 acts systemically. No hard pharmacokinetic conflict is documented, but both are research peptides not FDA-approved for human use. Cycle length, dose and injection site rotation still matter. Always confirm with a licensed clinician before combining.

There's no documented pharmacological interaction between BPC-157 and exogenous testosterone. BPC-157 does not appear to alter HPTA function. That said, BPC-157 is not FDA-approved and combining research peptides with hormone therapy adds monitoring complexity — blood work with your prescriber is the safest path.

There is no known direct interaction between GLP-1 receptor agonists and BPC-157. However, GLP-1s already slow gastric emptying and can cause nausea; adding gut-active peptides can compound GI side effects. Space injections apart, hydrate aggressively, and report any severe abdominal pain to your clinician immediately.

GHRH/GHRP peptides and TRT are commonly stacked, but the combination raises insulin resistance, water retention, and estrogen-conversion risks. It requires baseline and follow-up labs (fasting glucose, HbA1c, IGF-1, estradiol, hematocrit). Do not self-manage this stack without clinician oversight.

Avoid stacking two GLP-1 agonists (e.g. semaglutide + tirzepatide) — receptor competition and severe GI risk. Avoid combining melanocortin peptides (PT-141 + Melanotan II) — cardiovascular and pigmentation load. Never combine peptides with prescription medications without a clinician review.

Yes. Our library includes 450+ compounds — peptides classified as research-use-only in some jurisdictions are included for interaction cross-checking only. Listing a compound is not an endorsement of its use, legality, or safety in your jurisdiction.